APA’s policy team is working to update materials, but has informed members that the DEA and HHS issued a second temporary extension of COVID-19 telemedicine flexibilities for prescription of controlled medications, further extending exceptions to the existing DEA regulations through December 31, 2024. These telemedicine flexibilities authorize practitioners to prescribe schedule II-V controlled medications via audio-video telemedicine encounters, including III-V narcotic-controlled medications approved by FDA for the treatment of opioid use disorder via audio-only telemedicine encounters. The DEA is continuing to evaluate the feedback received during the comment period for the proposed rule and during the listening sessions held in September. They intend to promulgate new standards or safeguards by the fall of 2024.
Worth a Read
April 19, 2024
